Will the results be positive?
The intrinsic forecast suggests a 60% chance of a positive outcome, but the market price is currently at 51.86% for YES. Given the portfolio's cash availability and the max buy cap, a buy action is feasible. The expected... Steady-state cap reduced request to $542.53.
Intrinsic probability (78%) significantly exceeds the market price (~51%). The 27-point margin offers a strong positive expected value. Investing the maximum allowed amount capitalizes on this pricing inefficiency.
Intrinsic probability (65%) is materially above market price (51.3%), indicating YES shares are undervalued. With available cash and no portfolio constraints against buying, allocating the full maxBuyUsd to BUY_YES...
Biological risk of a Vero cell rabies vaccine failing an immunogenicity endpoint is negligible. At ~51%, the market drastically misprices this scientific near-certainty, likely over-penalizing a stale registry status.
Intrinsic 67% > market 51% (16% edge). Delay risk conservatively factored; undervalued YES. No position held; deploy max $1000 buy cap with ample cash.
